Askel Healthcare is a Finnish medical technology company set to transform surgical knee cartilage treatment and recovery. Founded in 2017, Askel develops unique solutions for rebuilding knee joint surfaces to help patients return quickly to a pain-free and active lifestyle. Its flagship product, the COPLA Cartilage implant, is a novel biodegradable solution designed to surgically treat knee cartilage damage, with Askel aiming for it to become the global standard for first-line surgical knee cartilage repair. The company has been granted FDA Breakthrough Device Designation for COPLA. With commercialization of the US market on the horizon, Askel needed to strengthen its Board with the right commercial and regional expertise to execute that strategy.
Challenge
One of the most common strategic gaps in early-stage and growth-stage MedTech companies is a Board that is built for the science rather than for the market. Founders and technical leadership teams are rarely the people best positioned to identify what the Board needs to look like three to five years out, and even when they know what they need, finding those individuals is a different problem entirely. Askel needed Board members with genuine commercial and regional expertise in the UK and US markets, people who understood how to navigate those environments at a senior level and who would add real strategic value as the company approached commercialization. That combination of functional depth, geographic experience, and Board-level seniority is not commonly available, and it is almost never found through a passive search.
Solution
Guided Solutions ran a proactive global search, engaging 300+ candidates across a wide geographical area. Thirty-eight comprehensive interviews were conducted before the field was narrowed to a shortlist of 13, giving Askel genuine optionality at Board level rather than a forced choice between two or three names. For MedTech startups approaching commercialization, Board composition is a strategic lever that is often underestimated. The right Board members open doors with investors and acquirers, provide credibility in new markets, and challenge leadership in ways that strengthen the business. Finding them requires the same rigour as any senior executive search, and the same access to people who are not actively looking.
Result
Two Board-level placements were completed within four months, equipping Askel with the commercial and regional expertise needed to pursue its UK and US commercialization strategy. For MedTech founders preparing for commercialization, the Askel case is a useful reference point on both timeline and process. A Board search that engages 300+ candidates, runs 38 interviews, and delivers two placements in four months is not a slow process. It is a thorough one. The difference matters, because a Board appointment made quickly from a short list of obvious names and a Board appointment made after a genuine global search rarely produce the same outcome.







